Skip to content

Homoeopathic treatment for reducing tobacco addiction in adults.

A comparative assessment of individualised Homoeopathic medicines and Nicotiana tabacum in fifty-millesimal (LM) potencies among adults with tobacco use disorder: an open-label, prospective and randomised study - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099799
Enrollment
60
Registered
2025-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F172- Nicotine dependence

Interventions

Intervention1: Individualised Homoeopathic Medicines(IHMs) group: IHMs intervention is planned as administering the most indicated Individualised Homoeopathic medicines in 50 millesimal /LM /Q potenci

Sponsors

North Eastern Institute of Ayurveda and Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects willing or motivated to quit or cut down the dependency on tobacco products. 2. Subjects aged 19 to 65 years, irrespective of gender or socioeconomic conditions. 3. Subjects fulfilling the diagnostic criteria of the DSM 5 diagnosis of TUD. 4. Subjects willing to provide informed consent in the study.

Exclusion criteria

Exclusion criteria: 1. Subjects having Tobacco addiction with other Psychoactive Substance abuse. 2. Coexisting dependent alcohol users. 3. Active psychiatric disorders requiring medication which include schizophrenia, bipolar disorder, major depressive disorder with suicidal ideation. 4. Other medical co morbidities like end stage organ failure, active malignancy, severe cardiovascular, respiratory disease, unstable angina pectoris or myocardial infarction. 5. Pregnant, puerperal, lactating women. 6. Self reported immunocompromised state. 7. Current use of any medications or pharmacotherapy for tobacco cessation. 8. Currently participating in or under any form of trial or research study. 9. Undergoing treatment for any chronic disease.

Design outcomes

Primary

MeasureTime frame
(1) The Fagerstrom Test for Nicotine Dependence (FTND); (2)The Fagerstrom Test for Nicotine Dependence-Smokeless Tobacco (FTND-ST) Timepoint: Baseline, 3rd and 6th months

Secondary

MeasureTime frame
Visual Analogue Scale (VAS)Timepoint: Baseline, 3rd and 6th months

Countries

India

Contacts

Public ContactBianghunlang Nongsiej

North Eastern Institute of Ayurveda and Homoeopathy

bianghunlang25@gmail.com7085719472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026